Target General Infomation
Target ID
T78381
Former ID
TTDI02296
Target Name
Interleukin-29 ligand
Gene Name
IFNL1
Synonyms
Cytokine Zcyto21; IFNlambda1; IL29; Interferon lambda1; Interleukin29; IFNL1
Target Type
Clinical Trial
Disease Acute myeloid leukemia [ICD9: 205; ICD10: C92.0]
Viral infections [ICD9: 054.0, 054.1, 054.2, 054.3, 075, 771.2, 052, 053; ICD10: B01, B02, A60, B00, B27, G05.1, P35.2]
Function
Cytokine withantiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN- stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type- selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.
BioChemical Class
Cytokine: interferon
UniProt ID
Sequence
MAAAWTVVLVTLVLGLAVAGPVPTSKPTTTGKGCHIGRFKSLSPQELASFKKARDALEES
LKLKNWSCSSPVFPGNWDLRLLQVRERPVALEAELALTLKVLEAAAGPALEDVLDQPLHT
LHHILSQLQACIQPQPTAGPRPRGRLHHWLHRLQEAPKKESAGCLEASVTFNLFRLLTRD
LKYVADGNLCLRTSTHPEST
Drugs and Mode of Action
Drug(s) Peginterferon lambda-1a Drug Info Phase 3 Acute myeloid leukemia [524307]
PEG-Interferon lambda (IL-29) Drug Info Phase 1 Viral infections [522171]
Agonist PEG-Interferon lambda (IL-29) Drug Info [531043]
Peginterferon lambda-1a Drug Info [531043]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
WikiPathways Type III interferon signaling
References
Ref 522171ClinicalTrials.gov (NCT00565539) Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection. U.S. National Institutes of Health.
Ref 524307ClinicalTrials.gov (NCT01866930) Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naive Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV. U.S. National Institutes of Health.
Ref 531043Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.